Laura Panjwani

Michael Morris, MD, discusses the potential of radium-223 and how the agent could be successful and impactful in metastatic castration-resistant prostate cancer.

Robert Figlin, MD, and Daniel Petrylak, MD, discuss emerging agents in RCC they are excited about and what challenges still remain in treating the disease.

Shaji Kumar, MD, discusses how newly approved agents and other changes have affected the treatment of multiple myeloma and what is on the horizon for the disease.

Roman Perez-Soler, MD, expanded on the importance of PD-1 inhibitors for all patients and the role of biomarker testing.

Robert J. Motzer, MD, discusses nivolumab's impact for renal cell carcinoma treatment.

Heather Wakelee, MD, reflected on the evolution of lung cancer treatment and just how significant of an impact immunotherapies may have.

PD-1/PD-L1 agents have shown significant potential for the treatment of urothelial bladder cancer, Daniel Petrylak, MD, from Yale Cancer Center, noted in a recent interview with OncLive.

Oliver Sartor, MD, expands on the impact of the STAMPEDE and CHAARTED trials and discusses how the results may change the treatment paradigm for prostate cancer going forward.

Alessandra Ferrajoli, MD, discusses the impact of the CLL11 and COMPLEMENT 1 trials, as well as other treatments that may be beneficial to the elderly chronic lymphocytic leukemia population.

Jennifer R. Brown, MD, PhD, discusses the future of chronic lymphocytic leukemia treatment.

The use of radiation therapy has declined despite evidence demonstrating it is often more beneficial than single-agent chemotherapy or observation-alone in patients with low-grade follicular lymphoma.

Dr. Ben Creelan, discusses the impact of the expanded approval of nivolumab in NSCLC and how the drug compares with pembrolizumab.

Dr. Noah Kauff discusses how hysterectomy, in addition to standard risk-reducing salpingo-oophorectomy (RRSO) measures, should be considered in BRCA+women to reduce the risk of serous uterine cancers.

Sylvia Adams, MD, explains the potential of TILs, as well as other biomarkers, including PD-1/PD-L1, in TNBC and other breast cancer types.

Leonard Saltz, MD, discusses antiangiogenesis and the use of VEGF inhibitors in colorectal cancer.

Robert Figlin, MD, discusses the evolution of TKIs in renal cell carcinoma, the novel agents and changes to established therapies he is most excited about, and the challenges that still remain.

Mohammad Jahanzeb, MD, discusses therapeutic agents that may fit into the adjuvant setting treatment paradigm for HER2-positive breast cancer, the increasing importance of genomic testing, and individualized treatments as multiple agents emerge.

George D. Demetri, MD, expands on the challenges with overall survival as a primary outcome measure, the potential of trabectedin in soft tissue sarcomas, and the significance of a recent trial.

Andrea B. Apolo, MD, explains the challenges that still remain regarding toxicity and future combination therapies with avelumab, and the potential of checkpoint inhibition in urothelial carcinoma going forward.

Naiyer A. Rizvi, MD, discusses the future outlook for PD-1/PD-L1 checkpoint agents in non-small cell lung cancer and the potential for immunotherapy combinations.

Immunotherapy expert Jeffrey Weber, MD, PhD, will join NYU Langone Medical Center's Laura and Isaac Perlmutter Cancer Center as its deputy director and co-director of its melanoma program.

Immunotherapy pioneer James P. Allison, PhD, has been named the 2015 recipient of the Lasker-DeBakey Clinical Medical Research Award by the Albert and Mary Lasker Foundation.

Joe O'Sullivan, MD, discusses how radium-223 dichloride (Xofigo), given with concomitant medication, may improve overall survival in patients with metastatic castration-resistant prostate cancer with bone metastases.

Hope Rugo, MD, discusses how to balance the benefits and risks of neratinib, as well as unanswered questions regarding ExteNET, in patients with HER2-positive breast cancer.

Renal cell carcinoma with sarcomatoid differentiation, a histology that is often resistant to targeted therapies and interleukin-2 immunotherapy (IL-2), may respond to anti–PD-1/PD-L1 therapies.

Dennis J. Slamon, MD, PhD, discusses the impact of the ADAPT and BOLERO trials and how the increased focus on neoadjuvant therapy with trastuzumab and T-DM1 could transform the treatment of HER2-positive breast cancer.

Tom Herzog, MD, discusses the vaccine ADXS11-001 (axalimogene filolisbac) in patients with persistent or recurrent metastatic cervical cancer.

Titrating dose levels of axitinib (Inlyta) improved response rates and extended overall survival by 12.3 months in patients with metastatic renal cell carcinoma.

Sanaz Memarzadeh, MD, PhD, discusses a combination regimen of birinapant and carboplatin in patients with high-grade serous ovarian cancers and high levels of cellular inhibitor of apoptosis protein (cIAP) in their CA-125–negative cells.

Marleen Meyers, MD, discusses rolapitant (Varubi), which the FDA recently approved to prevent delayed CINV.